clearly there is room for improvement. Few patients take interferon for the <10% or so cure rate as monotherapy, and I don't see why that will change here where you seem to get at best a comparable boost to bepi alone (i.e. no synergy was noted in this trial from what I can tell)
I had higher hopes bc the end of treatment responses on bepi alone were much higher, and if they could have maintained something close to that by adding interferon it would have been a huge improvement.
GSK has other combos in the works, a drug similar to the one ENTA shelved for toxicity for example, a vaccine etc. So they are throwing mud at the wall and hoping something sticks, and I don't see why trying a core inhibitor won't be something else they may want to try even though data on core inhibitors helping to drive down surface antigen is scant (one of the reasons I am curious about the upcoming late breaker from ALGS)
Market Data 
Markets 
AI
